Egetis’ Emcitate cleared by FDA for rare X-linked genetic disease
Egetis Therapeutics has secured US approval of its drug for a rare disease that shortens life expectancy to 35 years. The FDA on Monday backed tiratricol for certain patients with monocarboxylate ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.